Local antibacterial therapy in patients with diseases of the nasal cavity and paranasal sinuses, including against the background of cystic fibrosis

Acute respiratory viral infection is one of the most common infectious diseases. Clinical manifestations vary from time to time and from person to person and, as a rule, include intoxication and catarrhal syndromes. ARVI is more often caused by such causative agents as pneumoviruses, human metapneumovirus, coronaviruses, rhinoviruses, adenoviruses and bocaviruses. Among diseases of the ENT organs, ARVI can cause rhinosinusitis and pharyngitis. The inflammation that occurs in the mucosa causes its dystrophy and necrosis, which leads to the dysfunction of mucociliary clearance. As a result, an optimal environment for the development of bacterial flora is created. Bacterial rhinosinusitis needs antibiotic therapy. These drugs can act locally and systemically. It is well known that topical drugs have fewer side effects and result in a greater active substance concentration directly at a site of inflammation. Currently, a nasal framycetin spray is used as a topical antibacterial therapy to treat bacterial rhinosinusitis and in the early postoperative period. Topical drugs have a good evidence base, fewer side effects, and are safe, even for patients with cystic fibrosis. Given the significant antibiotics load in patients with cystic fibrosis, any opportunity to delay re-administration of antibiotics is a positive thing. In this aspect, topical antibiotics that have no systemic adverse events, including negative effects on the normal human microbiome, and can be used to overcome the resistance of microorganisms in a varying degree due to the achievement of high active substance concentration directly in a focus of infection may have a certain therapeutic value. The article addresses issues of epidemiology, pathogenesis, clinical manifestations of acute respiratory viral infection, i. e. acute rhinosinusitis. In addition, the article describes the use of topical antibiotic therapy for the treatment of diseases of the nasal cavities and paranasal sinuses.

1. Karpova L.S., Smorodintseva E.A., Sysoeva T.J., Stolyarova T.P., Popovtseva N.M., Stolyarov K.A. et al. The Spread of RS-virus Infection and other ARVI not Influenza Etiology in Children and Adults in the Regions of Russia from 2014 to 2016. Epidemiologiya i Vaktsinoprofilaktika. 2018;17(2):16–26. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-2-16-26.

2. Uchaikin V.F., Shamsheva O.V. Infectious diseases in children. Moscow: GEOTAR-Media; 2015. (In Russ.) Available at: https://www.studentlibrary.ru/book/ISBN9785970431658.html.

3. Lobzin Yu.V., Zhdanov K.V. Guide to Infectious Diseases. 4th ed. St Petersburg; 2011. 1408 p. (In Russ.)

4. Yushchuk N.D. Infectious diseases: national guidelines. Moscow: GEOTARMedia; 2018. 1004 p. (In Russ.) Available at: https://www.rosmedlib.ru/book/ISBN9785970444122.html.

5. Kiselev O.I., Sologub T.V., Romantsov M.G. Etiopathogenetic pharmacotherapy of SARS and influenza. Lechaschi Vrach. 2011;(2):92. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=21671800.

6. Karetkina G.N. The use of interferon inducers for the treatment and prevention of influenza and other acute respiratory viral infections. Lechaschi Vrach. 2009;(10):1–4. (In Russ.) Available at: https://www.lvrach.ru/2009/10/10861672.

7. Malkoch A.V., Anastasevich L.A., Botkina A.S. Acute respiratory diseases and possibilities of immunomodulatory therapy. Lechaschi Vrach. 2008;(8):58–62. (In Russ.) Available at: https://www.lvrach.ru/2008/08/5615064.

8. Pawankar R., Nonaka M. Inflammatory mechanisms and remodeling in chronic rhinosinusitis and nasal polyps. Curr Allergy Asthma Rep. 2007;7(3):202–208. https://doi.org/10.1007/s11882-007-0073-4.

9. Anand V.K. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl. 2004;193:3–5. https://doi.org/10.1177/00034894041130s502.

10. Yanov Yu.K., Ryazantsev S.V., Stratchounski L.S., Stetsiouk O.U., Kamanin E.I., Tarasov A.A. et al. Practice Guidelines on Antimicrobial Therapy of Sinusitis (Guidelines for clinicians). Klinicheskaia Mikrobiologiia i Antimikrobnaia Khimioterapiia. 2003;2(5):167–174. (In Russ.) Available at: https://cmac-journal.ru/publication/2003/2/cmac-2003-t05-n2-p167/cmac-2003-t05-n2-p167.pdf.

11. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/rhin20.600.

12. Jaume F., Valls-Mateus M., Mullol J. Common Cold and Acute Rhinosinusitis: Up-to-Date Management in 2020. Curr Allergy Asthma Rep. 2020;20(7):28. https://doi.org/10.1007/s11882-020-00917-5.

13. Karneeva O.V., Gurov A.V., Karpova E.P., Tulupov D.A., Ryazantsev S.V., Garashchenko T.I. et al. Acute sinusitis: Clinical Guidelines. 2021. (In Russ.) Available at: https://clck.ru/34P33V.

14. Svistushkin V.M., Sinkov E.V. Inflammatory diseases of the nasal cavity and paranasal sinuses. Role of topical therapy products. Meditsinskiy Sovet. 2016;(18):42–44. (In Russ.) https://doi.org/10.21518/2079-701X-2016-18-42-44.

15. Ryazantsev S.V., Krivopalov A.A., Eremin S.A., Shamkina P.A. Topical antibacterial therapy in the inflammatory diseases treatment of the nasal cavity, paranasal sinuses, and complications prevention. RMJ. 2019;8(I):55–59. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Topicheskaya_antibakterialynaya_terapiya_v_lechenii_vospalitelynyh_zabolevaniy_polosti_nosa_okolonosovyh_pazuh_i_profilaktike_osloghneniy.

16. Strachunsky L.S., Belousov Yu.B., Kozlov S.N. (eds.). A practical guide to anti-infective chemotherapy. Smolensk; 2007. (In Russ.) Available at: https://micropspbgmu.ru/micropspbgmu/Dopolnitelnye_istocniki_files/%D0%9F%D1%80%D0%B0%D0%BA%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%BE%D0%B5%20%D1%80%D1%83%D0%BA%D0%BE%D0%B2%D0%BE%D0%B4%D1%81%D1%82%D0%B2%D0%BE%20%D0%BF%D0%BE%20%D0%B0%D0%BD%D1%82%D0%B8%D0%B8%D0%BD%D1%84%D0%B5%D0%BA%D1%86%D0%B8%D0%BE%D0%BD%D0%BD%D0%BE%D0%B8%CC%86%20%D1%85%D0%B8%D0%BC%D0%B8%D0%BE%D1%82%D0%B5%D1%80%D0%B0%D0%BF%D0%B8%D0%B8.pdf.

17. Kunelskaya N.L., Turovsky A.B., Luchsheva Yu.V., Khamzalieva R.B., Izotova G.N. The role of topical antibiotics in the treatment of diseases accompanied by nasopharyngeal symptoms. Lechebnoe Delo. 2018;(1):60–65. https://doi.org/10.24411/2071-5315-2018-11984.

18. Kokorina V.E. Analysis of the results of the possibility of local therapy of acute rhinosinusitis as a complication of H1N1 influenza in frequently ill children. In: Materials of the VII St. Petersburg Forum of Otorhinolaryngologists of Russia. St Petersburg; 2018, pp. 65–66. (In Russ.) Available at: https://isofra.ru/analiz-rezultatov-vozmozhnosti-mestnoj-terapii-ostryhrinosinusitov-kak-oslozhnenij-grippa-h1n1-u-chasto-boleyushhih-detej.

19. Svistushkin V.M., Sinkov E.V., Nikiforova G.N. Role of topical antibacterial therapy in patients with cystic fibrosis. Vestnik Oto-Rino-Laringologii. 2021;86(4):59-66. (In Russ.) https://doi.org/10.17116/otorino20218604159.

20. Elkov I.V., Khabarov A.A. Investigation of penetration of morphocycline into the blood and maxillary sinus mucosa. Journal of Ear, Nose and Throat Diseases. 1991;(3):9–11. (In Russ.)

21. Abdulkerimov Kh.T., Artyushkin S.A., Aslanov B.I., Vakhrushev S.G., Garashchenko T.I., Gilifanov E.A. et al. The resolution of the nmao expert council on the problem of antibiotic therapy in otorhinolaryngology. Rossiiskaya Otorinolaringologiya. 2019;18(1):135–138. (In Russ.) Available at: https://elibrary.ru/item.asp?id=37051918.